Chemical Structure (Somavert 01)
Somavert Kit
Product Images NDC 0009-7166
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 46 technical images submitted to the FDA as part of the official labeling for Somavert (NDC 0009-7166). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Somavert 02)
This is a chart or table that provides the concentration of IGF-I and Free IGF-I in ng/mL in a study comparing the effects of placebo versus three different doses of SOMAVERT (10, 15, and 20 mg/day) over a 12-week period. The data is presented for each week on the x-axis and values are shown for each treatment group (placebo, 10 mg/day, 15 mg/day, and 20 mg/day) on the y-axis. There appears to be a significant increase in IGF-I concentration with SOMAVERT treatment compared to placebo.*
Figure 2 (Somavert 03)
The text is not available.*
Figure 3 (Somavert 04)
Logo (Somavert 05)
Figure (Somavert 06)
Figure (Somavert 07)
The text is providing labels and descriptions for various components of a syringe, vial, and needle guard. It is not a complete or coherent description of any particular product or function.*
Figure (Somavert 08)
This text provides guidelines for administering medication or treatment to specific parts of the body, including the arms or lower back, the upper area of the back, the abdomen, and the thighs. It also emphasizes the importance of having a healthcare provider or caregiver administer the treatment and emphasizes the need for proper placement when treating the abdomen, such as keeping it at least 2 inches (5cm) away from the belly button.*
Figure (Somavert 09)
Figure (Somavert 10)
Figure (Somavert 11)
This is a very short text that suggests a prompt to attach a safety needle. It doesn't provide any further details or context. Therefore, it can be interpreted as a reminder or an instruction to follow a particular procedure that involves attaching a safety needle.*
Figure (Somavert 12)
Figure (Somavert 13)
Figure (Somavert 14)
Figure (Somavert 15)
Figure (Somavert 16)
Figure (Somavert 17)
Figure (Somavert 18)
Figure (Somavert 19)
Figure (Somavert 20)
Figure (Somavert 21)
Figure (Somavert 22)
Figure (Somavert 23)
Logo (Somavert 24)
This text seems to be a simple guideline related to the acceptability of the presence of air bubbles and foam on a surface or material. It suggests that tiny air bubbles could be considered acceptable, but a layer of foam is not acceptable. It is not clear what context or industry this guideline applies to.*
Principal Display Panel (1 mL Syringe Label)
Principal Display Panel (10 mg Vial Label)
This is a description of a single-dose vial containing 1 mL of sterile water meant for injection purposes. It has an NDC number of 0009-5936-01 and is used for the reconstitution of SOMAVERT®. This solution does not contain any added substances, including antimicrobial properties. It is sterile and nonpyrogenic, with manufacturing done by Pramaci & Upon Compary LLC, a subsidiary of Pfizer. The location of manufacturing is given as New York, NY 10017, and the product's LOT/EXP R is provided as PAA171515.*
Principal Display Panel (10 mg Kit Carton)
This is a description of Somavert® which is a medication for injection with a strength of 10mg/vial. It is for subcutaneous use only and each vial is for single-dose use only. Any unused portion should be discarded. The NDC code for the medication is 0009-5175-02.*
Principal Display Panel (15 mg Vial Label)
This is a description of a Somavert single-dose vial containing 10 mg/vial of pegvisomant for injection. The contents of the vial include a diluent pre-filled syringe packed with 1 mL Sterile Water for Injection, USP and one 37 gauge ¥ inch safety needle. It is meant for subcutaneous injection only. Discard unused portion, and the manufacturing of the product was done by Eramec UO, and it is produced in Belgium.*
Principal Display Panel (15 mg Kit Carton)
Principal Display Panel (20 mg Vial Label)
Sr-Somavert® is a medication indicated for subcutaneous injection only, containing 10mg/vial of pegvisomant. The medication is provided in single-dose vials, and any unused portion must be discarded. The outer carton contains three intermediate cartons, each including ten single-dose vials of Somavert, thirty diluent prefilled syringes with 1 mL Sterile Water for Injection, USP, and thirty 27 gauge % Inch safety needles. Once reconstituted with 1 mL of Water for Injection, USP, the resulting concentration is 10mg/mL, with a pH between 7.1 107.7. The solution must be administered immediately. The medication contains no preservative and no US standard of potency. The text also provides storage instructions and Rx information and is manufactured by Pharmacia & Upjohn Company LLC, a subsidiary of Pfizer Inc., in Belgium.*
Principal Display Panel (20 mg Kit Carton)
This is a description for a medication called Somavert. It is an injection that contains 15 mg per vial and is for subcutaneous use only. The medication's active ingredient is pegvisomant. The packaging is a single-dose vial from the pharmaceutical company Pfizer, with the product code NDG 0009-5177-02. There is also a statement to discard a part identified as "umuser partion."*
Principal Display Panel (25 mg Vial Label)
This is a product description for Somavert®, a medication for injection. It is manufactured in Belgium and intended for subcutaneous use only. It comes in a single-dose vial with a pre-filled syringe containing 1 mL of sterile water for injection. It has a 27 gauge, 1 inch safety needle and contains 15 mg/vial of pegvisomant. The text also includes some irrelevant characters and numbers.*
Principal Display Panel (25 mg Kit Carton)
Principal Display Panel (30 mg Vial Label)
This is a medication called Somavert, which is injected subcutaneously only. Each vial contains 15mg pegvisomant, and the medication comes with diluent prefilled syringes and 27 gauge needles. The medication must be refrigerated at 2-8°C until reconstitution and use. After reconstitution, the solution must be used immediately. The medication should be used as prescribed, and the package includes instructions for administration. The outer carton comes with three intermediate cartons, containing ten vials each. Unused portions of the medication should be discarded. The medication is manufactured by Pharmacia & Upjohn Company LLC, a subsidiary of Pfizer Inc.*
Principal Display Panel (30 mg Kit Carton)
Somavert 36
The text appears to be a mix of different kinds of information such as company names, addresses, codes, and instructions. Therefore, it is not clear what is the information intended to describe. However, the text mentions a drug called Somavert which is a pegvisomant injection used for treating acromegaly and gigantism in adults. The drug comes in a single dose vial with a pre-filled syringe containing 1 ml sterile water for injection, USP and a 27 gauge ½ inch needle. It should be administered subcutaneously and any unused portion should be discarded.*
Somavert 37
Somavert is a medication administered through subcutaneous injection only. It comes in single-dose vials containing 20 mg/vial of the active ingredient "pegvisomant". Its intermediate carton contains ten single-dose vials and any unused portion must be discarded.*
Somavert 38
Sr-Somavert® (pegvisomant) is an injection used subcutaneously. It comes in single-dose vials and each box contains three intermediate cartons, each with ten single-dose Somavert vials, thirty diluent prefilled syringes containing 1 mL sterile water for injection, USP, and thirty 27 gauge 0.5 inch safety needles. The Diluent should be stored at a temperature from 2°C to 30°C (36°F) until the expiration date printed on the carton. The Somavert should be stored in the refrigerator at 2°C to 8% (30 to 46°F) before reconstitution and usage. The solution must be administered immediately after reconstitution with 1 mL of Water for Injection, USP, and the enclosed instructions must be followed for reconstitution and administration information. Dosage must be determined by a healthcare professional.*
Somavert 39
Somavert 40
Somavert® (pegvisomant) for injection is a medicine for subcutaneous injection only. The package contains one single-dose vial, one diluent prefilled syringe containing 1 L Sodium Chloride Injection, USP and R only, and one 37-gauge, 1/2-inch safety needle. Unused portion must be discarded. The product is marked NDC 0008-7109-01. Made in Belgium by a company named L0 RMECIAD E COMPARY SR T5S01 1L 5.*
Somavert 41
This is a description of Somavert (pegvisomant) for injection. It is intended for use in subcutaneous injections only, and comes in single-dose vials. The carton contains ten of these vials and any unused portions must be discarded.*
Somavert 42
Somavert® (pegvisomant) is a medication for subcutaneous injection only, available in single-dose vials. The medication must be stored and refrigerated between 2-8°C. Each intermediate carton contains ten single-dose vials of Somavert, along with 30 diluent prefilled syringes containing 1 mL sterile water for injection, USP with a concentration of 25 o and a pH between 5 to 7. The medication dosage is 50 Prasrog ornaton, and unused portions must be discarded. This drug is manufactured in Belgium by Pharmacia & Upjohn Company LLC. Rx only.*
Somavert 43
Somavert 44
"Somavert" is a medication for injection, manufactured in Belgium. It contains 30mg of the active ingredient "pegvisomant" and is intended for subcutaneous injection only. Each single-dose vial must be discarded if any portion goes unused. The medication comes with a syringe containing 1ml sterile water for injections, as well as a 27 gauge safety needle."*
Somavert 45
Somavert is a medicine that comes in single-dose vials of 30 mg/vial for subcutaneous injection only. The unused portion should be discarded. The text also includes some unreadable characters.*
Somavert 46
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
